Srini Akkaraju Akkaraju

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.

Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force.

Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York.

Barrier Therapeutics, Inc. discovers, develops, and commercializes pharmaceutical products in the field of dermatology in the United States. It markets Xolegel, Vusion, and Solage gels. The firm markets its products to dermatologists and other target physicians through sales force. The company was founded in 2001 and is headquartered in Princeton, NJ

PIramed Ltd. develops drugs, diagnostics, and other therapeutic products. It develops treatment for cancers which include proliferation, invasion, angiogenesis, and metastasis. The company was co-founded by Michael Waterfield, Peter Parker, and Paul Workman in 2003 and is headquartered in Slough, UK.

Synageva BioPharma's ultimate goal is to improve patient lives by providing access to breakthrough novel, next generation (i.e. significantly improved), and certain follow on protein therapeutics. Synageva's proprietary platform technologies, including SEP™, provide a number of sustainable competitive advantages for developing and commercializing these therapeutics including: high expression levels, more efficient purification processes, significantly reduced costs of production, rapid scalability, and consistency of end product. Its platform has already demonstrated its ability to produce a wide array of human therapeutic proteins including monoclonal antibodies (mAbs), cytokines, and other biotherapeutics. It has multiple compounds in development, including 2 monoclonal antibodies with enhanced ADCC activity, novel therapeutic proteins, and several cytokines including one with unique efficacy advantages. The commercialization strategy for these product candidates is designed to maximize its ability to rapidly develop and bring them to market so that they can address patients' unmet medical needs. The key elements of the strategy are to: 1. Establish partnerships to co-develop and commercialize select product candidates in large specialty markets 2. Independently develop and commercialize select novel product candidates that target high value orphan specialty markets 3. Establish partnerships to express proteins from other companies wanting to leverage the unique glycosylation advantages and other characteristics of the SEP™.

Itero Biopharmaceuticals, Inc. develops biopharmaceutical products for novel therapeutic proteins and antibodies. The firm focuses on the development and commercialization of protein therapeutics that offer significant clinical and commercial advantages over marketed alternatives. It provides recombinant follicle stimulating hormone for the treatment of female infertility. The company was founded in 2006 by Dr. V. Bryan Lawlis Jr., Dr. Darlene P. Horton and Roy Jerald Beers and is headquartered in Mountain View, CA.

Part of JPMorgan Chase & Co., JPMP Capital LLC is a venture capital firm. The company is based in New York, NY.

ZS Pharma, Inc. engages in the development of development and commercialization of non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases. It develops treatment of hyperkalemia. It also focuses on clinical development, novel technology, and clinical trials. The company was founded by Alvaro F. Guillem and Donald Jeffrey Keyser on February 5, 2008 and is headquartered in San Mateo, CA.

Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA.

Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California.

J.P. Morgan Partners LLC is a private equity firm founded in 1984. The firm headquartered located in New York City.

BioStreet, Inc. provided an on-line marketplace for biopharmaceutical deal making. The company was headquartered in San Francisco, CA.

New Leaf Venture Partners LLC (New Leaf Ventures) is an independent Venture Capital firm founded by Jeani Delagardelle, Philippe Chambon, Vijay Lathi, Ron Hunt, James Niedel, and Kathy LaPorte. The firm is headquartered in New York. It spun out from Sprout Group.

Panorama Capital LLC (Panorama Capita) is a venture capital firm founded in 1995 by Chris Albinson, Rod Ferguson, Shahan Soghikian and damion wicker. The firm is headquartered in Campbell, California.

Presidio Pharmaceuticals, Inc. discovers and develops small-molecule antiviral therapeutics. Its products in pipeline include NS5A, PPI-668 and PPI-383 for treating hepatitis C virus infections. The company was founded by Omar K. Haffar, Antoun Nabhan and David V. Jobes in March 2006 and is headquartered in San Francisco, CA.

Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA.

The George Institute for Global Health provides research and development for international health. It develops tools to empower people to improve their own health. The firm also uses mobile technology to make healthcare accessible worldwide and improves outcomes among stroke survivors. It helps preventing complications of diabetes. The company was founded by Stephen MacMahon and Robyn Norton in 1999 and is headquartered in Sydney, Australia.

Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA.

Samsara Biocapital LP invests in companies located in the US. The fund targets companies operating in the fields of biotechnology and pharmaceuticals. It provides financing for early stage capital requirements.

Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California.

Part of Samsara Biocapital LLC, Samsara Biocapital GP, LLC provides investment advisory services. The company is based in Palo Alto, CA. The company was founded by Srinivas Akkaraju.

A2 Biotherapeutics, Inc. operates as a biotechnology company. It develops medicines. The company was founded by Alexander Kamb, Michael Gallo and Paul Kang in 2018 and is headquartered in Westlake Village, CA.

Dewpoint Therapeutics, Inc. develops drugs. The company is headquartered in Boston, MA.

Mirobio Ltd. operates as a biologics company focusing on autoimmune and inflammatory disorders. The firm develops antibody modulators of immune cell receptors, an approach that has potential across a range of diseases, with an initial focus on auto-immune disease. The company was founded by Richard Cornall and Simon Davis on October 8, 2018 and is headquartered in Oxford, the United Kingdom.

Chinook Therapeutics, Inc operates as a biotechnology company, which engages in the development of medicines for kidney diseases. The company is headquartered in Vancouver, Canada.

Biopharma Co. Ltd. is a South Korean pharmaceutical company that manufactures pharmaceutical ingredients. The company is based in Gunpo, South Korea and was founded in 2019.

Chinook Therapeutics U.S., Inc. operates as a development stage company. The company is headquartered in Seattle, WA.

Synthekine, Inc. engages as a biotechnology company. The company is headquartered in Menlo Park, CA.

565 SPV I LP provides investment services. The company is headquartered in Palo Alto, CA.

Piper Biosciences, Inc. manufactures and sells cholesterol-lowering gummies with plant sterols. It offers cholesterol wellness kits.The company was founded by Rajiv Doshi and is headquartered in Los Altos, CA.

Tentarix Biotherapeutics LP operates as a biotechnology company. The company is headquartered in La Jolla, CA.

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.

Jiya Acquisition Corp. is a blank check company. The firm was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It focuses on identifying promising opportunities in the biopharmaceutical sector. The company was founded in August 2020 and is headquartered in Palo Alto, CA.

Autobahn Labs, Inc. is a virtual incubator that partners with research institutions to accelerate the advancement of early-stage drug discovery and development. The company is based in Palo Alto, CA. The organization invests intellectual, financial, and physical capital to efficiently move projects from feasibility to novel drug candidates. Autobahn Labs was created by Samsara Biocapital, Evotec, and KCK Ltd.

Codex Health, Inc. is a company based in Palo Alto, CA. Codex Health specializes in disease management with AI-powered clinical intelligence. The company's products enable healthcare organizations to deliver better outcomes, reduce costs, and improve the overall patient experience. Codex Health, Inc. offers a modern approach to chronic disease management, providing personalized care that is seamlessly linked to the patient's care team. Codex Health also offers next-generation population health management, equipping patients with personalized experiences and supporting them in their self-care journey. The company provides targeted proactive care, identifying at-risk patients and managing them proactively to mitigate adverse events. Codex Health's solutions enable scalable continuous and asynchronous care, extending clinical care into the patient's daily life. The company also helps healthcare systems maximize revenue by optimizing patients' outcomes based on deep clinical and operational visibility into risk and outcomes. The company was founded by Murari Srinivasan and Srinivas Akkaraju, with Murari Srinivasan serving as the CEO since incorporation.

Eyebiotech Ltd. develops new generation of therapies for eye diseases. The British company was founded in 2021 by David R. Guyer, Anthony P. Adamis. David R. Guyer has been the CEO since 2021.

Orsobio, Inc. is a clinical-stage biopharmaceutical company that focuses on developing therapies to treat obesity and other severe metabolic disorders, such as type 2 diabetes, NASH, and severe dyslipidemias. The company is based in Palo Alto, CA. The company has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism. Orsobio has a team of physicians and scientists who are dedicated to developing therapies to treat organ failure in patients with severe metabolic disorders. The company was founded by Mani Subramanian, who has been the CEO since incorporation.